Par Pharmaceutical Companies, Inc. (NYSE:PRX)

CAPS Rating: 4 out of 5

The Company, through its subsidiary Par Pharmaceutical, Inc., is engaged in the development, manufacture and distribution of generic pharmaceuticals and branded pharmaceuticals in the United States.

Results 1 - 20 of 24 : 1 2 Next »

Recs

0
Member Avatar valuefocusgroup (< 20) Submitted: 4/5/2011 9:23:07 AM : Outperform Start Price: $32.00 PRX Score: +7.47

Debt/equity of zero, Price/earnings of 12.28, market cap of 1.12 billion, Return on Invested Capital (TTM) of 15.81, based in New Jersey, United States, focus on generic drugs.

Recs

0
Member Avatar Covestor (34.62) Submitted: 3/11/2011 3:28:38 PM : Underperform Start Price: $30.41 PRX Score: -13.64

Covestor Model Manager Alphamark Advisors sold PRX in his Small Cap Growth Covestor Model ( http://covestor.com/Alphamark-Advisors )

Recs

0
Member Avatar pulpchamber (< 20) Submitted: 2/12/2010 5:05:49 PM : Outperform Start Price: $25.14 PRX Score: +17.11

Quality company with great growth!!

Recs

0
Member Avatar TALICAS101 (< 20) Submitted: 1/19/2010 8:40:58 PM : Outperform Start Price: $27.09 PRX Score: +11.41

Drugs Pick

Recs

0
Member Avatar donsguesswork (< 20) Submitted: 11/25/2009 9:19:24 PM : Outperform Start Price: $23.90 PRX Score: +26.65

Par pharmaceutical co is a holding company in the business of developing, manufacturing and distributing branded and generic drugs in the U.S. Earnings increased each of the last 3 qtrs., beating estimates by wide margin. Par sports of d/e .Per share T/B $9.93 Cash $6.04, and short interest 3.52%.

Recs

0
Member Avatar IGUESS2 (25.27) Submitted: 11/17/2009 10:43:24 PM : Outperform Start Price: $23.89 PRX Score: +31.43

Par Pharmaceutical Companies is a holding company in the business of developing, manufacturing and distributing generic and branded drugs in the U.S. Par sports a D/E of .15, cash per share $6.04. cash flow $2.18 and a short interest of 3.52%. Earnings surged each of the last three quarters and pulverized estimates.

Recs

0
Member Avatar Superman2bad4u (78.44) Submitted: 4/29/2009 11:35:46 AM : Outperform Start Price: $11.19 PRX Score: +218.24

With the swine flu pandemic I only see the majority of pharmaceutical companies doing good

Recs

0
Member Avatar TheHague (55.27) Submitted: 4/8/2009 7:38:13 PM : Outperform Start Price: $10.87 PRX Score: +223.74

With larger coverage, larger sales force, larger everything in general the B-12 nasal spray will meet Par's profit requirements nicely. Anyone who has to take pills every day will appreciate a one time per week nasal spray! The population is aging. B-12 is something all of us old hippies can get busy with!

Recs

0
Member Avatar stevez24 (66.97) Submitted: 3/26/2009 11:25:30 AM : Outperform Start Price: $11.05 PRX Score: +208.85

obama health plan increases use of generics

Recs

0
Member Avatar Helteninvest (< 20) Submitted: 1/2/2009 12:47:31 PM : Outperform Start Price: $13.35 PRX Score: +155.43

Over the next 3 years, $48B of branded drugs will go off patent, which will lead to generic drugs growing to 70 percent of the U.S. drug market place - PRX is strongly positioned ot take advantage of this shift in the marketplace

Recs

0
Member Avatar tikiskis (73.45) Submitted: 2/5/2008 3:19:35 PM : Outperform Start Price: $19.48 PRX Score: +103.11

Two words will boost this company: baby boomers. That combined with a faling health care system that intentionally plunges people into poverty will make discount drugs the place to be.

Granted, the above is only a justification for why this niche INDUSTRY will be good in the long term. There are still legitimate concerns about the financials on this company. However, given its place in foreign markets and the risk factor for any pharma company (especially one undercutting the majors), this is a bet that I believe will pay off.

Recs

0
Member Avatar SteadySaber (71.65) Submitted: 9/28/2007 12:35:02 PM : Underperform Start Price: $17.07 PRX Score: -156.94

No growth for 2008. Street hates that.

Recs

0
Member Avatar dustbusterz (< 20) Submitted: 8/23/2007 10:52:17 PM : Underperform Start Price: $22.82 PRX Score: -76.87

wow - take a look at the stats on this company. right at the moment, it appears to be beating the market as far as stock appreciation goes, but this baffles me . they have a net loss on growth,net loss on profit margins,operating margins are slim to say the least,dwindling cash flow charts. if you look at the balance sheet, you'll find a shrinking net assets base.revenues have shrunken to the negative area.this is a train wreck company. perhaps only weeks from announcing bankruptcy. my bet is ,someone has to take notice soon and this one will lag the market.

Recs

0
Member Avatar vicres (57.16) Submitted: 7/20/2007 9:33:08 PM : Underperform Start Price: $24.60 PRX Score: -68.13

Pure speculation

Recs

0
Member Avatar kcoyotee (< 20) Submitted: 7/19/2007 5:25:46 PM : Outperform Start Price: $25.22 PRX Score: +63.94

Great supply infrastructure in India, awesome business relationships with foreign regulators and markets. Model is lwo cost meds (generics) for tose not able to afford or be covered for other. PRX is all partners with up and coming and old time Pharmas..Alot in the pipe and alot in Phase3 ready for endorsement by foreign regulators.

Recs

0
Member Avatar rammsteinman (89.62) Submitted: 7/4/2007 4:50:31 AM : Outperform Start Price: $30.30 PRX Score: +28.33

cant lose with pharmaceuticals right now

Recs

0
Member Avatar TMFStockPick07 (< 20) Submitted: 5/21/2007 6:27:16 PM : Outperform Start Price: $28.51 PRX Score: +38.36

This stock was picked to outperform from May 2007 to May 2008 by TMFRobert

Recs

0
Member Avatar Spooky27 (98.67) Submitted: 3/4/2007 10:31:08 PM : Outperform Start Price: $23.29 PRX Score: +62.38

Well this company is health the eps is -0.05 but the chart show a possiable turn around there maybe room for profitablity but growth will be slow,not so good!

Recs

0
Member Avatar ICHIBANKOI (29.41) Submitted: 2/26/2007 5:05:46 PM : Outperform Start Price: $24.55 PRX Score: +57.67

Has buyout written all over them

Recs

2
Member Avatar 00746angel (< 20) Submitted: 2/18/2007 8:28:31 PM : Outperform Start Price: $24.43 PRX Score: +60.35

shipping out new approved drugs
as fast as they can produce them
pipe lines need to be filled
also esclusive rights for six months

Results 1 - 20 of 24 : 1 2 Next »

Featured Broker Partners


Advertisement